Profiles

Marret Howard

Research Coordinator

TRAININGS & QUALIFICATIONS

  • Electronic Diaries: sponsor/vendor training (2 yrs)
  • CSSR-S: sponsor/national training; certificate may be available
  • Centrifuge: by site, including cup size, RPMs, and calibrations (2 yrs)
  • EKG Acquisition: site training per cardiologist; lead placement per sponsor recommendations; conducting for 2 yrs
  • EKG Transmissions: per sponsor and vendor training; both computer/phone line (2 yrs)
  • Vitals: include temp, wt, ht, BP, HR; site training; manual/automatic BP; oral, temporal, auricle temp (2 yrs)
  • IATA: computer training; current certificate holder
  • EDC Experience: sponsor training; includes Medidata Rave, Pfizer DataLabs, InForm, PhaseForward, Oracle, and Perspective My Trials (2 yrs)
  • GCP CITI: current certificate holder
  • Questionnaires: sponsor/national training; includes PAC-QOL, PAC-SYM, Disease Severity, Disease QOL, Global Symptom Relief, Global Pain Relief, HADS, MIDAS, Treatment Satisfaction
  • IBS Rome III Diagnostic Criteria (2 yrs)
  • Rapid Result Labs: include drug screening, nicotine, pregnancy, urine dip stick (2 yrs)
  • ABI/TBI: sponsor & national training (2 yrs)
  • Lab Sample processing: sponsor, central lab specific, local lab, & site training (2 yrs)

CLINICAL RESEARCH

  • Vitality – A randomized, parallel-group, placebo-controlled, double-blind, multi-center trial to evaluate the efficacy and safety of the oral SGC stimulator vericiguat to improve physical functioning in activities of daily living in patients with heart failure and preserved ejection fraction.  BAY 1021189-19334
  • Evaluate HF – A multicenter, randomized, double-blind, double-dummy, parallel group, active-controlled, forced-titration, 12-week comparison of combined angiotensin-neprilysin inhibition with sacubitril and valsartan versus enalapril on changes in central aortic stiffness in patients with heart failure and reduced ejection fraction.  CLCZ696BUS08
  • Traverse – Testosterone replacement therapy for assessment of long-term vascular events and efficacy response in hypogonadal men.  ABBVIE M16-100
  • Amplitude – A randomized, double-blind, placebo-controlled, multicenter study to evaluate the effect of efpeglenatide on cardiovascular outcomes in Type 2 Diabetes patients at high cardiovascular risk. SANOFI EFC 14828
  • Prove – A 52 week, open-label evaluation of the effects of sacubitril/valsartan (LCZ696) therapy on biomarkers, myocardial remodeling and patient – reported outcomes in heart failures with reduced left ventricular ejection fraction.
  • R-Pharm (CL04041025 – Credo 3): A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-ą) Inhibitor Therapy
  • R-Pharm (CL04041023 – Credo 2): A Randomized, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Methotrexate Therapy
  • R-Pharm (CL04041024 – CREDO 4) – A Multi-center, open-label, Phase 3 study of the efficacy and safety of Olokizumab in Subjects with Moderately to severely active Rheumatoid Arthritis.
  • Alder Migraine – A parallel-group, Double-Blind, Randomized, Placebo-controlled trial to evaluate the efficacy and safety of ALD403 administered intravenously in patients with frequent episodic migraines and an open label trial to evaluate the safety of ALD403 administered intravenously in patients with frequent episodic migraines.
  • CoLucid COL MIG-305 (GLADIATOR): An Open-label, Long-term, Safety Study of Lasmiditan (100 mg and 200 mg) in the Acute Treatment of Migraine (GLADIATOR)
  • CoLucid COL MIG-302 (SPARTAN): A Study of Three Doses of Lasmiditan (50 mg, 100 mg, and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A randomized, double-blind, placebo-controlled parallel group study (SPARTAN)
  • Braintree BLI400-303: An Open Label Study of Chronic Use of BLI400 Laxative in Constipated Adults
  • Synergy Irritable Bowel Syndrome with Constipation: Second Phase 3 Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
  • Synergy: Irritable Bowel Syndrome with Constipation: An Open-Label, Long-Term Safety and Tolerability Study of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)
  • Voyager-PAD:  An international, multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures.
  • Redual PCI:  A prospective randomized, open label, blinded endpoint (PROBE) study to evaluate DUAL antithromotic therapy with dabigatran etexilate (110 mg and 150 mg BID) plus Clopidogrel or Ticagrelor vs. triple therapy strategy with Warfarin (INR 2.0 – 3.0) plus Clopidogrel or Ticagrelor and aspirin in patients with non valvular atrial fibrillation (NVAF) that have undergone a percutaneous coronary intervention (PCI) with stenting
  • Pfizer:   A Twelve Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study with Follow Up Evaluating the Safety and Efficacy of Varenicline for Smoking Cessation in Healthy Adolescent Smokers Ages 12 – 16.  Phase 4- Varenicline (Chantix)
  • Cempra: Phase III: A Randomized, Double-Blind, Multi-Center Study to Evaluate the Efficacy and Safety of Intravenous to Oral Solithromycin (CEM-101) Compared to Intravenous to Oral Moxifloxacin in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia